Table 1.
Authors or protocol ID | Sample size | Interventions | Targeted disease | Response rate |
---|---|---|---|---|
Weppelmann and Monkemeier52 | 76 vs. 84 (control) | Oxyphenbutazone | Cervical cancer | 5-year survival rate : 70% vs. 55% 10-year survival rate : 62% vs. 44% |
Hefler et al.57 | 8 vs. 8 (control) | Rofecoxib | CIN* 2–3 | 25% vs.12.5% |
Farley et al.58 | 12 vs. 13 (control) | Celecoxib | CIN* 2–3 | 75% vs. 31% |
Herrera et al.59 | 31 | Celecoxib | Cervical cancer | 81% |
Gaffney et al.60 | 84 | Celecoxib | Cervical cancer | Toxicity: 48% |
NCT00081263† (GOG-0207) | 100 | Celecoxib | CIN* 2–3 | - |
NCT00152828† | 45 | Celecoxib | Cervical cancer | - |
NCT00072540† (SWOG-S0212) | 100 | Celecoxib | CIN* 2–3 | - |
Cervical intraepithelial neoplasia;
Active clinical trials (available at http://clinicaltrials.gov).